300 related articles for article (PubMed ID: 31537619)
1. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
4. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
5. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
7. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
8. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN; Spowart JE; Huwait H; Eshragh S; West NR; Elrick MA; Kalloger SE; Anglesio M; Watson PH; Huntsman DG; Lum JJ
PLoS One; 2013; 8(12):e82406. PubMed ID: 24376535
[TBL] [Abstract][Full Text] [Related]
9. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
Yildirim N; Akman L; Acar K; Demir S; Ozkan S; Alan N; Zekioglu O; Terek MC; Ozdemir N; Ozsaran A
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():55-61. PubMed ID: 28601728
[TBL] [Abstract][Full Text] [Related]
10. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
11. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract][Full Text] [Related]
12. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
13. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
Wolf D; Wolf AM; Rumpold H; Fiegl H; Zeimet AG; Muller-Holzner E; Deibl M; Gastl G; Gunsilius E; Marth C
Clin Cancer Res; 2005 Dec; 11(23):8326-31. PubMed ID: 16322292
[TBL] [Abstract][Full Text] [Related]
14. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
Martin de la Fuente L; Westbom-Fremer S; Arildsen NS; Hartman L; Malander S; Kannisto P; Måsbäck A; Hedenfalk I
Virchows Arch; 2020 Jul; 477(1):83-91. PubMed ID: 31980961
[TBL] [Abstract][Full Text] [Related]
16. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
17. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
19. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
[TBL] [Abstract][Full Text] [Related]
20. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
